Tackling dementia together via the Australian Dementia Network (ADNeT): a Summary of initiatives, Progress and Plans
SL Naismith, JC Michaelian, C Santos… - Journal of …, 2023 - content.iospress.com
In 2018, the Australian Dementia Network (ADNeT) was established to bring together
Australia's leading dementia researchers, people with living experience and clinicians to …
Australia's leading dementia researchers, people with living experience and clinicians to …
Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure capability …
JC Michaelian, CC Rowe, SE Kurrle, CD Pond… - medRxiv, 2024 - medrxiv.org
Background: New amyloid-targeting monoclonal antibody (mAb) therapies for Alzheimer's
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …
Carer burden and behavioral disturbance is similar between younger-onset Alzheimer's disease and behavioral variant frontotemporal dementia
Objectives: Carer burden is common in younger-onset dementia (YOD), often due to the
difficulty of navigating services often designed for older people with dementia. Compared to …
difficulty of navigating services often designed for older people with dementia. Compared to …
Clinical Quality Indicators for Monitoring Hospitalizations Among Older People with Dementia Accessing Aged Care Services
JK Sluggett, T Air, M Cations… - Journal of …, 2023 - content.iospress.com
Background: There is a need for clinical quality indicators (CQIs) that can be applied to
dementia quality registries to monitor care outcomes for people with Alzheimer's disease …
dementia quality registries to monitor care outcomes for people with Alzheimer's disease …
[PDF][PDF] Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure …
CD Pond, M Woodward, SL Naismith, JC Michaelian… - medrxiv.org
Background: New amyloid-targeting monoclonal antibody (mAb) therapies for Alzheimer's
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …